← Back to Search

Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis

Phase 3
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose. Participants will complete the modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ) following the simulated injection. This study involves one study visit.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants Who Responded Agree or Strongly Agree to the Confidence of Use Question Using the mSQAAQ
Number of Participants Who Responded Agree or Strongly Agree to the Ease of Use Question Using the Modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Lebrikizumab PenExperimental Treatment1 Intervention
Injection of lebrikizumab pen into a practice pad.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lebrikizumab Pen
2024
Completed Phase 3
~60

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,679 Previous Clinical Trials
3,465,698 Total Patients Enrolled
Study DirectorEli Lilly and Company
4 Previous Clinical Trials
1,136 Total Patients Enrolled
~37 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top